Health Economics›Breast cancer›Metastatic disease all lines of therapy

Metastatic disease all lines of therapy

Breast cancer · 27 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Medroxyprogesterone acetate monotherapy Variant #01	ER	R 20 823	28d	—	~6.0 mo	~2	~R 41 646 PFS proxy · indirect	1
CAF and MPA Variant #01	ER	R 12 933	28d	—	—	~3	~R 38 799 indirect	—
Chlorambucil and Prednisolone Variant #01	—	R 6 773	21d	—	—	~3	~R 20 245 indirect	—
Mitoxantrone monotherapy Variant #01	—	R 5 139	21d	—	—	~2	~R 10 278 indirect	—
CAFVP Variant #01	—	R 2 559	28d	—	—	~7	~R 9 796 indirect	—
Estradiol monotherapy Variant #01	ER	R 2 346	28d	—	—	~2	~R 4 693 indirect	—
CEFT Variant #01	—	R 1 813	21d	—	—	~8	~R 14 505 indirect	—
CMFV Variant #01	—	R 1 715	28d	—	—	~2	~R 3 430 indirect	—
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	22.3 mo	1	R 1 680 PFS proxy	—
Doxorubicin and Etoposide Variant #01	—	R 1 364	21d	—	—	~16	~R 21 484 indirect	—
Fluorouracil and Methotrexate (MF) Variant #01	—	R 948	28d	—	—	~3	~R 2 369 indirect	—
CMFP Variant #01	—	R 813	28d	—	—	~6	~R 4 875 indirect	—
CAMF Variant #01	—	R 702	28d	—	—	~21	~R 10 690 indirect	—
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	~10.0 mo	~2	~R 1 294 PFS proxy · indirect	3
CFP Variant #01	—	R 500	42d	—	—	~10	~R 4 996 indirect	—
TAD (Tamoxifen) Variant #01 Partial	ER	R 487	28d	—	—	~2	~R 974 indirect	—
CMFVP Variant #01	—	R 399	7d	—	—	~52	~R 13 207 indirect	—
Fluoxymesterone and Tamoxifen Variant #01 Partial	ER	R 137	28d	—	—	~2	~R 273 indirect	—
Melphalan monotherapy Variant #01	—	R 73	42d	~50.0 mo	~22.2 mo	~9	~R 660 PFS proxy · indirect	7
Aminoglutethimide monotherapy Variant #01 Partial	ER	—	28d	—	—	~2	—	—
Thiotepa monotherapy Variant #01 Partial	—	—	3d	—	—	~1	—	—
Formestane monotherapy Variant #01 Partial	ER	—	14d	—	—	~2	—	—
Bilateral oophorectomy Partial	ER	—	—	—	—	—	—	—
Methotrexate and Thiotepa Partial	—	—	—	—	—	—	—	—
Megestrol monotherapy Variant #01 Partial	ER	—	28d	—	—	~2	—	—
DES monotherapy Variant #01 Partial	ER	—	28d	—	—	~2	—	—
Fluoxymesterone monotherapy Variant #01 Partial	ER	—	28d	—	—	~2	—	—

27 of 27 regimens shown